Gastroenteritis in Pediatric Population of Qatar (GE)

Epidemiology of Acute Gastroenteritis in the Pediatric Population in Qatar: Causes, Risk Factors, Burden of Disease, Sources and Preventable Measures

Comparison of clinical and laboratory diagnosis for cause of Gastroenteritis(GE) depending on the clinical manifestation.Identifying the sources of viral, bacterial and parasitic GE in Pediatric population of Qatar

Study Overview

• Status: Recruiting
• Conditions: Gastroenteritis
• Intervention / Treatment: Diagnostic test: Molecular method (PCR)

Detailed Description

Processing of stool samples by molecular method (PCR) for children with GE including complete data collection. Patients are followed up for 14 days

• Study Type: Observational
• Enrollment (Estimated): 3000

Contacts and Locations

• Study Contact: Name: Dr.Khalid Alansari; Phone Number: +974 55336166; Email: kalansari1@hamad.qa

Study Locations

• Qatar
  • Doha, Qatar, 3050
    • Recruiting
    • Hamad Medical Corporation
    • Contact: Dr.Khalid M Alansari, MD,FRCPC,FAAP(PEM); Phone Number: +97444396006 +97455336166; Email: KALANSARI1@hamad.qa

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 months to 14 years (Child)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

All acute gastroenteritis patients between 3 months to 14 years presenting to PEC centers with acute diarrhea+/- vomiting with or without fever

Description

Inclusion Criteria:

• All acute gastroenteritis patients between 3 months to 14 years presenting to PEC centers with acute diarrhea+/- vomiting with or without fever

Exclusion Criteria:

1. Cases of vomiting +/- fever only without diarrhea
2. Suspicion of surgical abdomen
3. Bile stained vomitus
4. Mal-absorption diseases as cystic fibrosis, celiac disease or increased secretion as disaccharides deficiency
5. Cases of Inflammatory bowel disease
6. Antibiotic associated diarrhea
7. Patients with immune deficiency
8. Patients with chronic diarrhea (>2 weeks of diarrhea)
9. Patients receiving long term medication for any disease

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
sources of viral, bacterial and parasitic GE in the country	Prevalence of viral, bacterial and parasitic GE in children < 14 years of age in Qatar will be identified by molecular method sample processing	4 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
seasonal variation of GE in qatar determination	seasonal variation of GE in qatar being determined by number of cases reported during each season	4 years
comparing the prevalence of viral GE in vaccinated children in Qatar (against rotavirus) and the other countries which implemented rotavirus vaccine	comparing the prevalence of viral GE in vaccinated children in Qatar (against rotavirus) and the other countries which implemented rotavirus vaccine by detection of source of GE in vaccinated children by molecular method.	4 years

Collaborators and Investigators

• Sponsor: Hamad Medical Corporation

Study record dates

Study Major Dates

• Study Start (Actual): March 10, 2015
• Primary Completion (Estimated): September 10, 2024
• Study Completion (Estimated): December 10, 2024

Study Registration Dates

• First Submitted: January 31, 2017
• First Submitted That Met QC Criteria: February 5, 2017
• First Posted (Estimated): February 8, 2017

Study Record Updates

• Last Update Posted (Actual): March 22, 2024
• Last Update Submitted That Met QC Criteria: March 21, 2024
• Last Verified: February 1, 2023

More Information

Terms related to this study

• Keywords: Gastroenteritis, Polymerase chain reaction
• Additional Relevant MeSH Terms: Digestive System Diseases; Gastrointestinal Diseases; Gastroenteritis
• Other Study ID Numbers: 14-00045

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No